Press Releases

Subscribe
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 20, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu

Read more
Mar 11, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Read more
Mar 10, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Read more
Mar 6, 2026
2026
Press Release Regulatory

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Regulatory
Read more
Feb 27, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Read more
Feb 18, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Read more
Feb 13, 2026
2026
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025

Regulatory
Read more
Feb 11, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Read more
Jan 22, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ CSO invited to present at multiple scientific conferences

Read more
Jan 9, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors

Read more
Dec 23, 2025
2025
Press Release Regulatory

Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory
Read more
Nov 14, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025

Regulatory
Read more
Nov 13, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Read more
Oct 23, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory
Read more
Sep 19, 2025
2025
Press Release Non-regulatory

Elicera clarifies status of the iTANK-platform patent application in the U.S.

Read more
Aug 29, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025

Regulatory
Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy

Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee’s Assessment in Cohort 2

Read more
Jun 11, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics postpones final reporting of ELC-100 study due to database transition

Read more
May 28, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company’s oncolytic virus candidates, ELC-100 and ELC-201

Read more

Sign up for Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.